Scientific publications

Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP)

Sanchez-Salcedo P (1), Berto J [SP] (1), de-Torres JP [SP] (1), Campo A [SP] (1), Alcaide AB [SP] (1), Bastarrika G [SP] (2), Pueyo JC [SP] (2), Villanueva A (2), Echeveste JI [SP] (3), Lozano MD [SP] (3), García-Velloso MJ [SP] (4), Seijo LM (5), García J (6), Torre W (7), Pajares MJ (8), Pío R (8), Montuenga LM (8), Zulueta JJ (9).
(1) Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, España.
(2) Departamento de Radiología, Clínica Universidad de Navarra, Pamplona, España.
(3) Departamento de Anatomía Patológica, Clínica Universidad de Navarra, Pamplona, España.
(4) Departamento de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España.
(5) Departamento de Neumología, IIS - Fundación Jiménez Díaz, CIBERES, Madrid, España.
(6) Departamento de Neumología, Clínica Universidad de Navarra, Madrid, España.
(7) Departamento de Cirugía Torácica, Clínica Universidad de Navarra, Pamplona, España.
(8) Centro de Investigación Médica Aplicada - CIMA, Universidad de Navarra, Pamplona, España.
(9) Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, España 

Magazine: Archivos de Bronconeumología

Date: Apr 1, 2015

Lung Cancer Area Radiology [SP] Pneumology Thoracic Surgery Pathological Anatomy [SP] Nuclear Medicine [SP]

INTRODUCTION AND OBJECTIVES
European experience regarding lung cancer screening using low-dose chest CT (LDCT) is available. However, there is limited data on the Spanish experience in this matter. Our aim is to present the results from the longest ongoing screening program in Spain.

METHODOLOGY
The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) is actively screening participants for lung cancer using LDCT since year 2000 following the IELCAP protocol, including spirometric assessments. Men and women, ≥40 years of age, current or former smokers with a tobacco history of ≥10 pack-years are included. Results are compared to those from other European trials.

RESULTS
A total of 2989 participants were screened until March 2014 (73% male). A median of 2 (IQR 1-3) annual screening rounds were performed. Sixty lung cancers were detected in 53 participants (73% in StageI). Adenocarcinoma was the most frequent.

The lung cancer prevalence and incidence proportion was 1.0% and 1.4%, respectively, with an annual detection rate of 0.41. The estimated 10-year survival rate among individuals with lung cancer was 70%. Chronic obstructive pulmonary disease and emphysema are important lung cancer predictors.

CONCLUSIONS
The experience in Spain's longest lung cancer screening program is comparable to what has been described in the rest of Europe, and confirms the feasibility and efficacy of lung cancer screening using LDCT.

CITATION  Arch Bronconeumol. 2015 Apr;51(4):169-76. doi: 10.1016/j.arbres.2014.09.019. Epub 2015 Jan 29

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra